JP2015502368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502368A5 JP2015502368A5 JP2014547553A JP2014547553A JP2015502368A5 JP 2015502368 A5 JP2015502368 A5 JP 2015502368A5 JP 2014547553 A JP2014547553 A JP 2014547553A JP 2014547553 A JP2014547553 A JP 2014547553A JP 2015502368 A5 JP2015502368 A5 JP 2015502368A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- compound
- composition according
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940024606 amino acid Drugs 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 33
- 208000017442 Retinal disease Diseases 0.000 claims description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 24
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 24
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 22
- 235000004279 alanine Nutrition 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 16
- 150000002576 ketones Chemical class 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 239000004474 valine Substances 0.000 claims description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 208000002780 macular degeneration Diseases 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- 210000001525 retina Anatomy 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 4
- 230000003278 mimic effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 150000008575 L-amino acids Chemical class 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims description 2
- 208000036584 Optic disc drusen Diseases 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- -1 amino, hydroxyl Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 210000004177 elastic tissue Anatomy 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 208000001491 myopia Diseases 0.000 claims description 2
- 230000004379 myopia Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000004233 retinal vasculature Effects 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 2
- 206010073286 Pathologic myopia Diseases 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576720P | 2011-12-16 | 2011-12-16 | |
| US61/576,720 | 2011-12-16 | ||
| PCT/US2012/070190 WO2013090931A2 (en) | 2011-12-16 | 2012-12-17 | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017156321A Division JP2018024674A (ja) | 2011-12-16 | 2017-08-14 | 網膜の障害および疾患の治療のためのａｎｐ（心房性ナトリウム利尿ペプチド）、ｂｎｐ（脳性ナトリウム利尿ペプチド）およびｃｎｐ（ｃ型ナトリウム利尿ペプチド）−関連ペプチドならびにそれらの誘導体の方法および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015502368A JP2015502368A (ja) | 2015-01-22 |
| JP2015502368A5 true JP2015502368A5 (cg-RX-API-DMAC7.html) | 2015-11-05 |
Family
ID=48613379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547553A Withdrawn JP2015502368A (ja) | 2011-12-16 | 2012-12-17 | 網膜の障害および疾患の治療のためのａｎｐ（心房性ナトリウム利尿ペプチド）、ｂｎｐ（脳性ナトリウム利尿ペプチド）およびｃｎｐ（ｃ型ナトリウム利尿ペプチド）−関連ペプチドならびにそれらの誘導体の方法および使用 |
| JP2017156321A Pending JP2018024674A (ja) | 2011-12-16 | 2017-08-14 | 網膜の障害および疾患の治療のためのａｎｐ（心房性ナトリウム利尿ペプチド）、ｂｎｐ（脳性ナトリウム利尿ペプチド）およびｃｎｐ（ｃ型ナトリウム利尿ペプチド）−関連ペプチドならびにそれらの誘導体の方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017156321A Pending JP2018024674A (ja) | 2011-12-16 | 2017-08-14 | 網膜の障害および疾患の治療のためのａｎｐ（心房性ナトリウム利尿ペプチド）、ｂｎｐ（脳性ナトリウム利尿ペプチド）およびｃｎｐ（ｃ型ナトリウム利尿ペプチド）−関連ペプチドならびにそれらの誘導体の方法および使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150045301A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2790714A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2015502368A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104039341A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2853204A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1202433A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013090931A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106822182A (zh) * | 2016-12-27 | 2017-06-13 | 广州姿生生物科技有限公司 | 一种细胞提取物及其用途 |
| US11419917B2 (en) | 2020-04-07 | 2022-08-23 | Drora Shevy | Treatment for SARS-CoV-2 and other coronaviruses |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| JPH10273450A (ja) * | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| EP1727556A2 (en) * | 2004-02-17 | 2006-12-06 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| US20070049251A1 (en) | 2005-08-31 | 2007-03-01 | Mock Von A | Method and system for wireless communication in emergency situations |
| WO2009043437A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| RU2010114029A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Астрессин и бета-эндорфин для применения в качестве терапевтических средств |
| US20100204090A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| WO2009033762A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of endothelin-3 as a therapeutic agent |
| JP2011509248A (ja) * | 2007-12-28 | 2011-03-24 | カルロス・セラピューティクス、インク | 抗細胞増殖化合物およびその使用方法 |
| US8546523B2 (en) * | 2009-09-25 | 2013-10-01 | Alcon Research, Ltd. | NPR-B agonists |
| US8551938B2 (en) * | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
| WO2011075471A2 (en) * | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
-
2012
- 2012-12-17 WO PCT/US2012/070190 patent/WO2013090931A2/en not_active Ceased
- 2012-12-17 CN CN201280062142.XA patent/CN104039341A/zh active Pending
- 2012-12-17 JP JP2014547553A patent/JP2015502368A/ja not_active Withdrawn
- 2012-12-17 HK HK15103021.0A patent/HK1202433A1/xx unknown
- 2012-12-17 CA CA2853204A patent/CA2853204A1/en not_active Abandoned
- 2012-12-17 US US14/365,517 patent/US20150045301A1/en not_active Abandoned
- 2012-12-17 CN CN201810139954.9A patent/CN108653715A/zh active Pending
- 2012-12-17 EP EP12858180.8A patent/EP2790714A4/en not_active Withdrawn
-
2017
- 2017-08-14 JP JP2017156321A patent/JP2018024674A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sheibani et al. | Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization | |
| ES2468827T3 (es) | Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada | |
| JP2020055866A (ja) | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 | |
| JP6666899B2 (ja) | Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法 | |
| JP7280619B2 (ja) | ペプチド組成物 | |
| JP2014511858A5 (cg-RX-API-DMAC7.html) | ||
| JP7726791B2 (ja) | 補体活性を調節するための組成物及び方法 | |
| ES2755053T3 (es) | Composición para el tratamiento de lesiones cerebrales | |
| WO2015142855A1 (en) | Compositions and methods for treating retinopathy | |
| US20200222548A1 (en) | Synthetic bioconjugates | |
| CN116917482A (zh) | 嵌合蛋白和治疗中枢神经系统疾病的方法 | |
| KR20200026918A (ko) | 화학적으로 변형된 백본을 갖는 생체접합체 | |
| JP7423070B2 (ja) | 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ | |
| AR079683A1 (es) | Formulacion topica oftalmica de peptidos | |
| Jiang et al. | Eyedrop delivery of therapeutic proteins with zwitterionic polymers to treat dry age-related macular degeneration | |
| JP2015502368A5 (cg-RX-API-DMAC7.html) | ||
| JP2018536650A5 (cg-RX-API-DMAC7.html) | ||
| WO2019048852A1 (en) | TREATMENT OF NEURODEGENERATIVE DISEASES | |
| WO2008075365A1 (en) | Compositions and methods for treatment of age related degeneration of the retina | |
| WO2011097577A2 (en) | Compositions and methods for treating or preventing retinal degeneration | |
| CN106714821A (zh) | Jnk信号转导途径的细胞穿透肽抑制剂用于治疗多种疾病的新用途 | |
| JP6046060B2 (ja) | エイズの治療のための、ポリアニオン性ポリペプチドと結合しているｃｄ４受容体由来ペプチドを含んでなる新規コンジュゲート分子 | |
| US9913877B2 (en) | Methods and compositions for the treatment of axonal and neuronal degeneration | |
| WO2025022842A1 (ja) | ドライアイの治療剤又は予防剤 | |
| JP2023504731A (ja) | タウオパチーを処置するためのペプチド組成物及び方法 |